Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) on Focus After Report of Less Shorts

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) Logo

The stock of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) registered a decrease of 11.19% in short interest. NVIV’s total short interest was 249,300 shares in May as published by FINRA. Its down 11.19% from 280,700 shares, reported previously. With 35,800 shares average volume, it will take short sellers 7 days to cover their NVIV’s short positions. The short interest to Invivo Therapeutics Holdings Corp’s float is 2.68%.

The stock decreased 3.91% or $0.0485 during the last trading session, reaching $1.1915. About 23,815 shares traded. InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) has declined 87.15% since May 14, 2018 and is downtrending. It has underperformed by 91.52% the S&P500.

InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, focus on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries . The company has market cap of $11.09 million. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for acute SCI; and Therapeutic Trails injection program for the treatment of chronic SCI. It currently has negative earnings.

More notable recent InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) news were published by: which released: “​With Trumpian flair, former CEO of InVivo announces unsolicited takeover offer – Boston Business Journal” on January 04, 2017, also with their article: “How InVivo CEO Mark Perrin plans to own the spine injury market – Boston Business Journal” published on July 27, 2015, published: “InVivo Revolutionizing Spinal Cord Injury – Seeking Alpha” on March 27, 2015. More interesting news about InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) were released by: and their article: “Matinas BioPharma Holdings, Inc. 10-K Apr. 1, 2019 4:53 PM – Seeking Alpha” published on April 01, 2019 as well as‘s news article titled: “InVivo’s Therapy On The Verge Of Becoming The De Facto Treatment For Spinal Cord Injury – Seeking Alpha” with publication date: March 09, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.